ResultsIQ

ResultsIQ › Latest results › Rossari Biotech Limited

Rossari Biotech Limited Q3 FY26 earnings call summary

NSE: ROSSARI · BSE: 543213

Earnings call of 19 Jan 2026, summarised by AI from the filing.

Rossari Biotech Q3 FY26 revenue up 13% YoY to ₹581.7 cr; margins guided at 12%-13% for next year.

Key takeaways

  1. Revenue Q3 FY26 consolidated revenue ₹581.7 cr, up 13% YoY, despite softer domestic demand.
  2. KSA approval Board granted in-principle approval for greenfield specialty chemicals facility in Saudi Arabia.
  3. EO constraint Ethylene Oxide availability remains a near-term constraint; additional volumes expected by Q3 FY27.

Original filing on BSE

Rossari Biotech Limited Q1 FY27 results

As filed: Revenue ₹697 cr (+28% year on year), EBITDA ₹80.6 cr (+17% year on year), PAT ₹35.1 cr (+3% year on year), EBITDA margin 11.6% (−112 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹685 cr (+18% year on year), EBITDA ₹77.3 cr (+10% year on year), PAT ₹46.0 cr (+35% year on year), EBITDA margin 11.3% (−79 bps). Score 67 of 100, Above trend. Revenue and EBITDA growth were above the company's own trend; profit growth was well above it. EBITDA margin fell 79 bps year on year. Other income 30% of PBT. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +6.5% in 30 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹582 cr (+13% year on year), EBITDA ₹68.9 cr (+8% year on year), PAT ₹32.8 cr (+2% year on year), EBITDA margin 11.8% (−64 bps). Score 52 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit growth was below it. EBITDA margin fell 64 bps year on year. Revenue rose ₹68.7 cr on a year ago, more than the ₹49.0 cr it added the year before. Share price after the results: +0.7% in 30 days (Nifty 500: −0.1%).
  • H1 FY26: Revenue ₹1,130 cr, EBITDA ₹140 cr, PAT ₹70.0 cr, EBITDA margin 12.4%. Not scored. No consolidated results for the same half-year last year to compare yet (consolidated revenue ₹1,130 cr). Scored once a year-earlier consolidated half-year exists. Share price after the results: −4.6% in 30 days (Nifty 500: +2.0%).
  • Q1 FY26: Revenue ₹544 cr (+11% year on year), EBITDA ₹69.0 cr (+6% year on year), PAT ₹34.0 cr (−3% year on year), EBITDA margin 12.7% (−58 bps). Score 36 of 100, Below trend. Revenue and EBITDA growth were below the company's own trend; profit growth was well below it. EBITDA margin fell 58 bps year on year. Revenue fell 6% from last quarter. Share price after the results: −14.0% in 30 days (Nifty 500: −1.5%).
  • Q4 FY25: Revenue ₹580 cr (+23% year on year), EBITDA ₹70.0 cr (+9% year on year), PAT ₹34.0 cr (0% year on year), EBITDA margin 12.1% (−146 bps). Score 50 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was in line with it; profit growth was below it. EBITDA margin fell 146 bps year on year. Share price after the results: −5.9% in 28 days (Nifty 500: +4.3%).
  • Q3 FY25: Revenue ₹513 cr (+11% year on year), EBITDA ₹64.0 cr (+2% year on year), PAT ₹32.0 cr (−6% year on year), EBITDA margin 12.5% (−110 bps). Score 24 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 110 bps year on year. Profit fell 9% from last quarter.
  • Q2 FY25: Revenue ₹498 cr (+3% year on year), EBITDA ₹66.0 cr (+3% year on year), PAT ₹35.0 cr (+6% year on year), EBITDA margin 13.3% (0 bps). Score 38 of 100, Below trend. EBITDA margin was flat year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Rossari Biotech Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.